Determining potential immunomodulatory drug efficacy in sepsis using ELISpot

Area of Science:

• Immunology
• Pharmacology
• Sepsis Research

Background:

• Sepsis involves complex immune dysregulation.
• Identifying effective immunomodulatory therapies for sepsis remains challenging.

Purpose of the Study:

• To evaluate the ELISpot assay's capability in assessing immunomodulatory drug efficacy in sepsis.
• To analyze the impact of drugs on both innate and adaptive immune responses.

Main Methods:

• Ex vivo ELISpot assays on whole blood from septic patients and healthy controls.
• Measurement of Tumor Necrosis Factor-alpha (TNF-α) for innate immunity and Interferon-gamma (IFN-γ) for adaptive immunity.
• Assessment of drug effects on cytokine production per cell and total cytokine output.

Main Results:

• LPS and resiquimod significantly boosted TNF-α production in septic patients.
• Dexamethasone suppressed LPS- and resiquimod-induced TNF-α production.
• IL-7 markedly increased IFN-γ production in both healthy and septic individuals, while dexamethasone suppressed it; IL-7 counteracted this suppression.

Conclusions:

• ELISpot assays can reveal host immune profiles and drug-specific immune modulation in sepsis.
• This method's ability to differentiate effects on innate and adaptive immunity supports precision immune-based drug development for sepsis.